national
FDA Approves Moderna's mFlusiva as First mRNA Influenza Vaccine
Just the facts
The U.S. Food and Drug Administration granted approval for Moderna's mFlusiva influenza vaccine designated for adults aged 50 and older. Full approval for individuals aged 50 to 64 was supported by a 40,000-participant trial demonstrating a 27 percent reduction in flu cases compared to existing vaccines, while adults aged 65 and older received accelerated approval pending postmarketing trials. The vaccine utilizes messenger RNA technology, enabling accelerated manufacturing adjustments to match evolving seasonal flu strains.
Why this is news
The U.S. Food and Drug Administration approved Moderna's mFlusiva, marking the first influenza vaccine manufactured using messenger RNA technology.
Sources
This summary is compiled strictly from the original reporting below.